A long-standing Wall Street belief that the global obesity-drug market would climb to about $150 billion over the next decade is now being called into question, as U.S. prices for GLP-1 medications from Novo Nordisk and Eli Lilly begin to decline.
A long-standing Wall Street belief that the global obesity-drug market would climb to about $150 billion over the next decade is now being called into question, as U.S. prices for GLP-1 medications from Novo Nordisk and Eli Lilly begin to decline.
Popular Posts
Join the official YWN WhatsApp status
